Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology


's stock had its "outperform" rating reiterated by research analysts at Credit Suisse Group in a report released on Tuesday, July 18th, Marketbeat Ratings reports. They currently have a $118.00 price objective on the biopharmaceutical company's stock, up from their previous price objective of $90.00.



from Biotech News